Table 3.
Outcome of HCTs in Adults from various centers in India.
| Ganapule et al. 11 | Kulkarni et al. 12 | Kumar et al.13 | Kumar et al.14 | Sharma et al.15 | Nair et al.16 | |
|---|---|---|---|---|---|---|
| Institute | CMC Vellore | CMC Vellore | AIIMS, New Delhi | Army Hospital Research&Referral, New Delhi | BLK Superspeciality Hospital, New Delhi | Army Hospital Research & Referral, New Delhi |
| N | 254 | 245 | 349 | 702 (Total) 188 (Pediatric) 514 (Adult) |
516 | 119 |
| Type of HCT | ||||||
| Autologous | 0 | 245 | 349 | 297 | 258 | 0 |
| Allogenic | 254 | 0 | 0 | 405 | 258 | 119 |
| Indication | ||||||
| Autologous∖1 | NA | Multiple Myeloma | Multiple Myeloma | Multiple Myeloma Hodgkin Lymphoma Non-Hodgkin Lymphoma |
Multiple myeloma Non-Hodgkin lymphoma Hodgkin lymphoma ALL |
NA |
| Allogenic∖1 | AML | NA | NA | AML Aplastic Anema ALL, CML MDS, PID |
AML | AML, ALL CML, JMML Thalassemia Major Acquired SAA MDS, PNH |
| Median age of patients (in years) | 09 (Pediatric) | |||||
| Autologous∖1 | NA | 51 | 52 | 42 (Adult) | 43 | NA |
| Allogenic | 34 | NA | NA | (Both autologous and allogenic combined) | NA | 17 |
| Median neutrophil engraftment day | ||||||
| Autologous | NA | 12 | NR | NR | NA | NA |
| Allogenic | NR | NA | NA | NR | NA | 11.3 |
| Median follow-up period | NA (Retrospective study) | 40.7 months | 73 months | NA (Retrospective study) | NA | 34 months |
| OS | 65% (Both autologous and allogenic combined) | |||||
| Autologous | NA | 61.6% ± 3.8% | 63.2% (5-year OS) | 69.75 (5-year OS) | NA | |
| Allogenic | 40.1 ± 3.5% (5-year OS) | NA | NA | 47.0% (5-year OS) | 62.3% | |
| PFS/EFS | ||||||
| Autologous HCT | NA | 37.2% ± 3.9% | 38.5% (5 years) | NR | 32.5% (5-year DFS) | NA |
| Allogenic HCT | 38.7 ± 3.4% (5-year DFS) | NA | NA | 41.8% (5-year DFS) | NR | |
| TRM | ||||||
| Autologous HCT | NA | 2.86% | 7.2% | NR | NA | |
| Allogenic HCT | 50.8% (1-year TRM) | NA | NA | 30.8% (Overall mortality) | 37.7% (Overall mortality) |